Onclive Team

Photos from the 2012 National Coalition of Oncology Nurse Navigators' (NCONN) annual conference that was held at the Gaylord Opryland Hotel from October 4th to 6th, in Nashville, Tennessee.

An interview with Giorgio V. Scagliotti, MD, who has played a prominent role in researching and developing therapies to attack molecular targets.

Photos from the 2012 European Society for Medical Oncology (ESMO) congress, held at the Austria Center Vienna from September 28 to October 2, in Vienna, Austria.

An exploratory analysis of the phase III AURELIA trial affirms the benefit of adding bevacizumab to chemotherapy for patients with platinum-resistant recurrent ovarian cancer.

Concurrent mutations in MEK1 and BRAF genes do not confer resistance to BRAF inhibitors in advanced melanoma, contrary to what investigators had expected.

Cabozantinib significantly prolonged progression-free survival in medullary thyroid cancer compared with placebo among patients with radiographically confirmed progressive disease at study onset.

Photos from the 82nd Annual Meeting of the American Thyroid Association held in Quebec City, Canada, on September 19-23, 2012.

The application of molecular markers is already significantly improving the diagnosis of thyroid cancer and broader application could help prevent unnecessary surgeries to confirm the diagnosis.

Four histopathologic features of papillary microcarcinoma help predict how aggressive the tumor will be and subsequently how aggressive treatment must be to prevent its spread.

OncLive presents live coverage from the 2012 NCONN Changing the Face of Cancer Care Conference, held at the Gaylord Opryland Hotel from October 4th to 6th, in Nashville, TN.

The availability of molecular agents that target oncogenic signaling pathways now offers the possibility of achieving disease stabilization in a proportion of patients with metastatic medullary thyroid cancer.

The initial surgical procedure performed for the management of medullary thyroid cancer is the best chance surgeons have for a cure.

Coverage from the 2012 European Society for Medical Oncology congress, held at the Austria Center Vienna from September 28 - October 2, in Vienna, Austria.

There are several issues in the Centers for Medicare & Medicaid Services 2012 fee schedule that are of concern to oncologists.

Patients with refractory non-small cell lung cancer had a statistically significant improvement in PFS when treated with targeted therapy duo versus a single agent.

A common mutation in NSCLC confers resistance to tyrosine kinase inhibitors and worsens survival, creating a need for an alternative approach to treating the subgroup of patients with the mutation.

Patients with advanced non-small cell lung cancer lived twice as long when they received an indirect angiogenesis inhibitor plus docetaxel instead of docetaxel alone.

The economics of running an oncology practice is forcing physicians to consider whether they should stay in private practice, join a large network or hospital, or become hospital employees.

A quick glance at a recent study examining the renal cell carcinoma immunotherapy AGS-003 and the FDA approval of a new noninvasive prostate health index test.

The Trials in Progress Poster Session at the ASCO Annual Meeting, now in its third year, is intended to stimulate discussion in the oncology community about ongoing clinical trials and to promote collaboration.

A brief introduction to the topics and focus of the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology.

Canadian researchers are investigating standard fractionation radiotherapy with concurrent high-dose cisplatin versus accelerated fractionation radiotherapy with panitumumab in locally SCCHN.

Pazopanib has demonstrated activity in a majority of patients with refractory urothelial cancer, providing the first evidence that targeted therapies might have a role in the disease.

Summaries of ongoing research underway in bladder, prostate, and renal cancer, intended to stimulate discussion about ongoing clinical trials and to promote collaboration across the urology community.

Trials underway in gastrointestinal, oral, head and neck, and brain cancer intended to stimulate discussion about ongoing clinical trials and to promote collaboration across the oncology community.

The American Society of Clinical Oncology has honored 11 people with distinguished awards in recognition of their special contributions to cancer care.

Smokers are better able to remember the printed health-risk warnings that appear in cigarette advertisements and labels when the messages include images.

Oncologists are all faced with the same challenge-delivering the best cancer care possible while reining in rising costs and one answer that many oncologists are looking at is cancer management systems.

Research presented at the ASCO Annual Meeting in June included these two clinical trials in advanced, metastatic non-small cell lung cancer.

Bortezomib represented a major discovery in cancer research and has helped some patients achieve a complete pathological response and live longer.